ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Otsuka Pharmaceutical has agreed to buy Avanir Pharmaceuticals for $3.5 billion. Avanir launched Nuedexta in 2011. It is used in the treatment of pseudobulbar affect, a neurological disease. The drug recorded U.S. sales of $94 million from July 2013 to June 2014, Otsuka says. The Japanese firm says it’s attracted to Avanir because of further market potential for Nuedexta and also because of Avanir’s R&D pipeline. Avanir is conducting research on the central nervous system to develop treatments for Parkinson’s, Alzheimer’s, migraines, and other ailments. It has an Alzheimer’s compound that is about to enter Phase III clinical trials.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X